Cortellini, A., Brunetti, L., Fazio, G. R. d., Garbo, E., Pinato, D. J., Naidoo, J., . . . Pecci, F. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: Results from the Pembro-real 5Y global registry.
Citación estilo ChicagoCortellini, Alessio, et al. Determinants of 5-year Survival in Patients With Advanced NSCLC With PD-L1≥50% Treated With First-line Pembrolizumab Outside of Clinical Trials: Results From the Pembro-real 5Y Global Registry. 2025.
Cita MLACortellini, Alessio, et al. Determinants of 5-year Survival in Patients With Advanced NSCLC With PD-L1≥50% Treated With First-line Pembrolizumab Outside of Clinical Trials: Results From the Pembro-real 5Y Global Registry. 2025.